VKTX
VKTX
US92686J1060
Viking Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
393.342.000 150.921.000
160.6%
Operating Income -393.342.000 -150.921.000
160.6%
Pretax Income -359.639.000 -109.963.000
227.1%
Net Income Common Stockholders -359.639.000 -109.963.000
227.1%
-- --
--
-- --
--
ende